Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)
      Google Scholar   
Citation:
Blood vol 130 (Suppl 1) 485
Meeting Instance:
ASH 2017
Year:
2017
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3045  
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                     
Networks:
CAPITAL, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-OH007, NC002, NY018   
Study
CALGB-50904
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: